Molecular Mechanisms Of Human Retrovirus Trans-regulator

$0Z01FY2003AINIH

Niaid Extramural Activities

Investigators

Linked publications & trials

Paper 19729508 Paper 19460752 Paper 19114009 Paper 18976462 Paper 18684817 Paper 18549828 Paper 18452151 Paper 18078512 Paper 18053150 Paper 17937800 Paper 17661632 Paper 17627941 Paper 17586323 Paper 17322031 Paper 17274823 Paper 17266578 Paper 17263586 Paper 17181864 Paper 16957379 Paper 16935887 Paper 16908165 Paper 16887810 Paper 16867898 Paper 16809310 Paper 16767081 Paper 16720895 Paper 16611882 Paper 16501612 Paper 16495226 Paper 16436385 Paper 16409294 Paper 16398928 Paper 16381609 Paper 16365316 Paper 16354572 Paper 16288203 Paper 16227293 Paper 16184083 Paper 16155604 Paper 16014171 Paper 16003825 Paper 16000174 Paper 15994832 Paper 15970479 Paper 15930259 Paper 15894278 Paper 15864735 Paper 15806143 Paper 15743525 Paper 15725354 Paper 15644139 Paper 15601472 Paper 15507209 Paper 15479810 Paper 15371436 Paper 15347421 Paper 15297062 Paper 15285791 Paper 15169569 Paper 15169558 Paper 15090550 Paper 15037192 Paper 14694097 Paper 14654787 Paper 14576468 Paper 12947089 Paper 12943661 Paper 12883554 Paper 12857725 Paper 12802280 Paper 12504126 Paper 12486002 Paper 12458222 Paper 12438582 Paper 12419799 Paper 12145525 Paper 12097320 Paper 12042300 Paper 12006501 Paper 11980658 Paper 11971966 Paper 11779707 Paper 11729202 Paper 11572598 Paper 11494144 Paper 11472235 Paper 11397795 Paper 11160720 Paper 11119608 Paper 11089618 Paper 11060498 Paper 10698967 Paper 10675342 Paper 10662613 Paper 10640540 Paper 10630961 Paper 10620360

Abstract

This project focuses on basic and applied research on human retroviruses, HIV-1 and HTLV-I. It covers three broad areas: I) basic research studying the regulated expression of HIV-1; II) basic research on cellular transformation events as related to HTLV-I; and III) applied research towards developing small molecular inhibitors targeted against HIV-1. Some notable scientific advances from our research program in 2002-2003 include: 1) the finding that human cyclin T1 has a transcriptional activation domain and can be recruited to the HIV-1 LTR by Sp1; 2) the characterization of small Tat pepetides which can be used to inhibit HIV-1 replication; 3) the identification of a small molecule which binds avidly to TAR RNA and which can inhibit HIV-1 replication; 4) the demonstration that the second exon of Tat contains an in vivo replication important function; 5) the finding that Tat is ubiquinated and that ubiquination of Tat does not dictate proteolysi; 6) the elucidation of different requirements for p300 and PCAF in the activation of integrated versus non-integrated HTLV-I LTR; and 7) the unexpected discovery that Tax can repress telomerase expression in human cells.

View original record on NIH RePORTER →